Evommune

Evommune Current Liabilities

The Current Liabilities of Evommune (EVMN) as of Oct 29, 2026 is 28.05 M USD. In the previous year, Current Liabilities was 32.73 M USD — a change of -14.31% (lower).

Current Liabilities

28.05 MUSD

YoY

-14.31%

Last updated:

Current Liabilities of Evommune is 2025 28.05 M USD. Current Liabilities of Evommune was 2024 32.73 M USD. It decreases by -14.31% lower compared to the previous year.

The Evommune Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2023
11.65 M USD
Jan 1, 2024
32.73 M USD
Jan 1, 2025
28.05 M USD
The Evommune Current Liabilities history
YEARCurrent LiabilitiesYoY
28.05 MUSD-14.31%
32.73 MUSD+180.88%
11.65 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evommune Stock analysis

What does Evommune do? Evommune Inc generates revenue through its research and development activities focused on inflammatory diseases. The company employs a tissue-based approach using skin as a lens to develop transformative medicines in immunology and dermatology. Its primary products are advanced therapeutic solutions for inflammatory conditions, targeting pharmaceutical companies seeking to accelerate drug development. The firm serves the biotechnology and pharmaceutical sectors with its innovative R&D services. The company's business model centers on providing specialized research services to accelerate medicine development. Evommune, Inc. leverages skin tissue insights to uncover new approaches for immunology and dermatology treatments. Its services are purchased by pharmaceutical firms aiming to enhance their drug development pipelines. The firm's R&D focus on inflammatory diseases positions it as a key partner for companies in the biotech industry. Evommune Inc's revenue streams come from contractual R&D services for pharmaceutical clients. The company's tissue-based methodology for inflammatory disease research is its core offering. It develops and delivers research insights that help clients advance their medicine development in immunology and dermatology. The firm's approach targets the biotechnology sector's need for faster, more effective drug development solutions. Evommune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evommune stock

Current Liabilities of Evommune is 28.05 M USD in 2025.

Current Liabilities of Evommune changed from 32.73 M USD to 28.05 M USD, representing a -14.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Evommune since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Evommune historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Evommune

All Key Metrics — Evommune